Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.

Reid EG, Suazo A, Lensing SY, Dittmer DP, Ambinder RF, Maldarelli F, Gorelick RJ, Aboulafia DM, Mitsuyasu R, Dickson MA, Wachsman W.

Clin Cancer Res. 2019 Oct 17. pii: clincanres.1044.2019. doi: 10.1158/1078-0432.CCR-19-1044. [Epub ahead of print]

PMID:
31624104
2.

Comparison of nylon-flocked swab and Dacron swab cytology for anal HSIL detection in transgender women and gay, bisexual, and other men who have sex with men.

Wiley DJ, Hsu HK, Ganser MA, Brook J, Elashoff DA, Moran MG, Young SA, Joste NE, Mitsuyasu R, Darragh TM, Morris DH, Martínez-Maza OM, Detels R, Rao JY, Bolan RK, Shigeno ET, Rodriguez E.

Cancer Cytopathol. 2019 Apr;127(4):247-257. doi: 10.1002/cncy.22114. Epub 2019 Mar 26.

PMID:
30913381
3.

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA.

PLoS One. 2019 Jan 30;14(1):e0210965. doi: 10.1371/journal.pone.0210965. eCollection 2019.

4.

Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, Ramos JC, Sparano J, Ambinder RF, Lee J, Cesarman E, Yahyaei S, Mitsuyasu R, Wachsman W; AIDS Malignancy Consortium.

Blood Adv. 2018 Dec 26;2(24):3618-3626. doi: 10.1182/bloodadvances.2018022095.

5.

Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India.

Sinha S, Agarwal A, Gupta K, Mandal D, Jain M, Detels R, Nandy K, DeVos MA, Sharma SK, Manoharan N, Julka PK, Rath GK, Ambinder RF, Mitsuyasu RT.

Curr HIV Res. 2018;16(4):315-320. doi: 10.2174/1570162X16666181018161616.

6.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

7.

A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium Trial.

Goldstone SE, Lensing SY, Stier EA, Darragh T, Lee JY, van Zante A, Jay N, Berry-Lawhorn JM, Cranston RD, Mitsuyasu R, Aboulafia D, Palefsky JM, Wilkin T.

Clin Infect Dis. 2019 Mar 19;68(7):1204-1212. doi: 10.1093/cid/ciy615.

8.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ.

J Clin Invest. 2018 Aug 31;128(9):4074-4085. doi: 10.1172/JCI120549. Epub 2018 Aug 20.

9.

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men.

Ellsworth GB, Lensing SY, Ogilvie CB, Lee JY, Goldstone SE, Berry-Lawhorn JM, Jay N, Stier EA, Logan JS, Einstein MH, Saah A, Mitsuyasu RT, Aboulafia D, Palefsky JM, Wilkin TJ.

Papillomavirus Res. 2018 Dec;6:11-14. doi: 10.1016/j.pvr.2018.05.001. Epub 2018 May 26. No abstract available.

10.

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).

Ramos JC, Sparano JA, Rudek MA, Moore PC, Cesarman E, Reid EG, Henry D, Ratner L, Aboulafia D, Lee JY, Ambinder RF, Mitsuyasu R, Noy A.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):180-190.e2. doi: 10.1016/j.clml.2018.01.004. Epub 2018 Feb 2.

11.

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden.

Dittmer DP, Krown SE, Mitsuyasu R.

JAMA Oncol. 2017 Oct 1;3(10):1429. doi: 10.1001/jamaoncol.2016.7092. No abstract available.

PMID:
28662221
12.

Reply to Meijide et al.

Borges ÁH, Neuhaus J, Babiker A, Wilkin T, Mitsuyasu R.

Clin Infect Dis. 2017 Feb 1;64(3):389-390. doi: 10.1093/cid/ciw760. Epub 2016 Nov 14. No abstract available.

PMID:
28013262
13.

Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.

Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ, Kachnic L, Mitsuyasu R.

J Clin Oncol. 2017 Mar;35(7):727-733. doi: 10.1200/JCO.2016.69.1642. Epub 2016 Dec 12.

14.

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.

Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT.

J Cancer Epidemiol. 2016;2016:2138259. Epub 2016 Nov 2.

15.

Clinical and scientific challenges in HIV-associated malignancies.

Polizzotto MN, Mitsuyasu RT.

Curr Opin HIV AIDS. 2017 Jan;12(1):1-5. No abstract available.

16.

HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India.

Godbole SV, Nandy K, Gauniyal M, Nalawade P, Sane S, Koyande S, Toyama J, Hegde A, Virgo P, Bhatia K, Paranjape RS, Risbud AR, Mbulaiteye SM, Mitsuyasu RT.

Medicine (Baltimore). 2016 Sep;95(37):e4850. doi: 10.1097/MD.0000000000004850.

17.

Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group.

Clin Infect Dis. 2016 Dec 15;63(12):1668-1676. Epub 2016 Sep 8.

18.

Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.

Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambinder R, Baiocchi R, Dezube BJ, Henry D, Kaplan L, Levine AM, Mitsuyasu R, Ratner L, Reid E, Remick S, Sparano J, Tzachanis D, Wachsman W, Chadburn A.

Leuk Lymphoma. 2016 Jul;57(7):1731-4. doi: 10.3109/10428194.2015.1113281. Epub 2015 Dec 16. No abstract available.

19.

Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles.

Pines HA, Gorbach PM, Weiss RE, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu RT.

AIDS Behav. 2016 Jun;20(6):1315-26. doi: 10.1007/s10461-015-1218-4.

20.

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O.

Clin Cancer Res. 2016 Jan 15;22(2):328-36. doi: 10.1158/1078-0432.CCR-14-0466. Epub 2015 Sep 17.

21.

Potential Use of Thioalkylated Mannose-Modified Dendrimer (G3)/α-Cyclodextrin Conjugate as an NF-κB siRNA Carrier for the Treatment of Fulminant Hepatitis.

Motoyama K, Mitsuyasu R, Akao C, Abu Hashim II, Sato N, Tanaka T, Higashi T, Arima H.

Mol Pharm. 2015 Sep 8;12(9):3129-36. doi: 10.1021/mp500814f. Epub 2015 Aug 20.

PMID:
26270769
22.

Design and evaluation of thioalkylated mannose-modified dendrimer (G3)/α-cyclodextrin conjugates as antigen-presenting cell-selective siRNA carriers.

Motoyama K, Mitsuyasu R, Akao C, Tanaka T, Ohyama A, Sato N, Higashi T, Arima H.

AAPS J. 2014 Nov;16(6):1298-308. doi: 10.1208/s12248-014-9665-9. Epub 2014 Sep 19.

23.

Non-AIDS-defining cancers.

Mitsuyasu RT.

Top Antivir Med. 2014 Jun-Jul;22(3):660-5. Review.

24.

Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention.

Pines HA, Gorbach PM, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu R.

AIDS Care. 2014;26(12):1609-18. doi: 10.1080/09540121.2014.936821. Epub 2014 Jul 15.

25.

Stage-stratified approach to AIDS-related Kaposi's sarcoma: implications for resource-limited environments.

Krown SE, Borok MZ, Campbell TB, Casper C, Dittmer DP, Hosseinipour MC, Mitsuyasu RT, Mosam A, Orem J, Phipps WT.

J Clin Oncol. 2014 Aug 10;32(23):2512-3. doi: 10.1200/JCO.2014.55.8999. Epub 2014 Jul 7. No abstract available.

26.

High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study.

Reddy D, Njala J, Stocker P, Schooley A, Flores M, Tseng CH, Pfaff C, Jansen P, Mitsuyasu RT, Hoffman RM.

Int J STD AIDS. 2015 May;26(6):379-87. doi: 10.1177/0956462414539149. Epub 2014 Jun 13.

27.

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.

Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW.

PLoS One. 2014 Mar 17;9(3):e92118. doi: 10.1371/journal.pone.0092118. eCollection 2014.

28.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

29.

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.

30.

Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers.

Borges ÁH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheuer G, Mitsuyasu R, Tambussi G, Sabin CA, Neaton JD, Lundgren JD; INSIGHT SMART; ESPRIT; SILCAAT Study Groups.

AIDS. 2013 Jun 1;27(9):1433-41. doi: 10.1097/QAD.0b013e32835f6b0c.

31.

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry MJ, Jay N, Aboulafia DM, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

HIV Clin Trials. 2013 Mar-Apr;14(2):75-9. doi: 10.1310/hct1402-75.

32.

Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytes.

Dong Q, Oh JE, Yi JK, Kim RH, Shin KH, Mitsuyasu R, Park NH, Kang MK.

Int J Mol Med. 2013 Jun;31(6):1305-12. doi: 10.3892/ijmm.2013.1327. Epub 2013 Apr 3.

33.

Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.

Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):438-41. doi: 10.1097/QAI.0b013e31828e6163.

34.

Curing HIV: lessons from cancer therapy.

Mitsuyasu R.

Curr Opin HIV AIDS. 2013 May;8(3):224-9. doi: 10.1097/COH.0b013e32835ef0a1. Review.

35.

Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection.

Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA.

AIDS. 2013 Jul 17;27(11):1735-42. doi: 10.1097/QAD.0b013e3283601144.

36.

Didanosine-associated retinal toxicity in adults infected with human immunodeficiency virus.

Gabrielian A, MacCumber MM, Kukuyev A, Mitsuyasu R, Holland GN, Sarraf D.

JAMA Ophthalmol. 2013 Feb;131(2):255-9. doi: 10.1001/jamaophthalmol.2013.579. No abstract available.

PMID:
23411900
37.

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A.

J Clin Oncol. 2013 Jan 1;31(1):58-64. doi: 10.1200/JCO.2012.42.4648. Epub 2012 Nov 19.

38.

Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.

Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT.

BMC Infect Dis. 2012 Jul 31;12:168.

39.

Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy.

Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, Khan NH, Mitsuyasu RT.

Curr HIV Res. 2012 Sep;10(6):532-8.

PMID:
22716105
40.

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.

Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A.

Leuk Lymphoma. 2012 Dec;53(12):2383-9. doi: 10.3109/10428194.2012.697559. Epub 2012 Jul 9.

41.

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH.

Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761.

42.

Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India.

Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, Samantaray JC, Sharma SK, Bhargava A, Pandey RM, Mitsuyasu RL, Fahey JL.

AIDS Res Treat. 2012;2012:905823. doi: 10.1155/2012/905823. Epub 2012 Mar 15.

43.

Meeting the challenge of hematologic malignancies in sub-Saharan Africa.

Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT.

Blood. 2012 May 31;119(22):5078-87. doi: 10.1182/blood-2012-02-387092. Epub 2012 Mar 28. Review.

44.

The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment.

Sinha S, Dhooria S, Kumar S, Shah N, Velpandian T, Ravi A, Kumar N, Ahmad H, Bhargwa A, Chug K, Bumma N, Chandrashekhar R, Ekka M, Sreenivas V, Sharma SK, Samantaray J, Mitsuyasu R.

AIDS Res Ther. 2011 Nov 2;8(1):41. doi: 10.1186/1742-6405-8-41.

45.

Challenges for conducting clinical trials for AIDS malignancies in resource-limited settings.

Mitsuyasu R.

Curr Opin Oncol. 2011 Sep;23(5):461-2. doi: 10.1097/CCO.0b013e32834a18d5. No abstract available.

46.

HIV-associated multicentric Castleman disease.

Reddy D, Mitsuyasu R.

Curr Opin Oncol. 2011 Sep;23(5):475-81. doi: 10.1097/CCO.0b013e328349c233. Review.

47.

Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Mitsuyasu RT, Zack JA, Macpherson JL, Symonds GP.

Stem Cells Int. 2011;2011:393698. doi: 10.4061/2011/393698. Epub 2011 Jun 13.

48.

Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals.

Hoffman RM, Jamieson BD, Bosch RJ, Currier J, Kitchen CM, Schmid I, Zhu Y, Bennett K, Mitsuyasu R.

J Clin Immunol. 2011 Oct;31(5):873-81. doi: 10.1007/s10875-011-9550-6. Epub 2011 Jun 4.

49.

Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R; ACTG-ALLRT Protocol Team.

Oncology. 2011;80(1-2):42-9. doi: 10.1159/000328032. Epub 2011 May 23.

50.

A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment.

Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R; AIDS Clinical Trials Group A5132 Team.

J Interferon Cytokine Res. 2011 Jun;31(6):481-3. doi: 10.1089/jir.2010.0119. Epub 2011 Feb 3.

Supplemental Content

Loading ...
Support Center